STAAR Surgical Reports Second Quarter 2023 Results

Rhea-AI Summary

STAAR Surgical Company (NASDAQ: STAA) reported financial results for Q2 2023. Net sales were $92.3 million, up 14% YoY. Record ICL sales reached $93.1 million, up 19% YoY. Gross margin was 76.6%, down from 78.8% in the prior year quarter. Net income was $0.12 per share, compared to $0.26 per share in the prior year quarter. Cash, cash equivalents, and investments totaled $209.5 million.

Positive

• Net sales increased by 14% YoY, reaching $92.3 million.
• Record ICL sales of $93.1 million, up 19% YoY.
• Gross margin decreased to 76.6% from 78.8% in the prior year quarter.
• Net income per share was $0.12, compared to $0.26 in the prior year quarter.
• Cash, cash equivalents, and investments totaled $209.5 million.

Negative

• Gross margin decreased by 2.2 percentage points.
• Net income per share decreased by 54%.
• ICL sales growth in EMEA markets was down 23%.

Record ICL Sales of $93.1 Million Up 19% Y/Y

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the second quarter ended June 30, 2023.

Second Quarter 2023 Overview

• Net Sales of $92.3 Million Up 14% includes a $0.7 Million sales reduction related to Other Products
• Record ICL Sales of $93.1 Million Up 19% Y/Y and Up 20% Y/Y in Constant Currency
• ICL Units Up 21% Y/Y
• Gross Margin at 76.6% vs. 78.8% in the Prior Year Quarter
• Net Income of $0.12 per Share vs. $0.26 per Share in the Prior Year Quarter
• Cash, Cash Equivalents and Investments Available for Sale Ended the Quarter at $209.5 Million
• Accounting adjustments related to Other Products resulted in Adjusted Net Sales of $93.0 Million; Adjusted Gross Profit Margin of 79.8% and Adjusted Net Income for ICL of $0.19 per Share.

“Record second quarter global ICL sales of $93.1 million up 19%, were driven by strength in our APAC region which generated 26% ICL sales growth,” said Tom Frinzi, President and CEO of STAAR Surgical. “The peak implant season for our proprietary family of EVO ICL lenses in China, the largest market for refractive procedures in the world, had a strong start in June, during which I had the pleasure of working with our team on the ground for several days. In APAC geographies, EVO has a strong market position and a long runway for growth. In the nascent U.S. market, ICL growth exceeded industry trends and although below our expectations we remain confident this market will achieve the growth levels we have seen in our other target markets. In the U.S. ICL sales were up 10% in the second quarter as compared to refractive industry procedures which were down 15%.¹ We have taken a number of steps and implemented initiatives that we expect will accelerate EVO adoption in the U.S. as we exit 2023 and beyond.”

Mr. Frinzi continued, “Given increased conservatism related to the global environment, and a revised near-term outlook for U.S. growth, we are updating our fiscal 2023 ICL sales outlook to a range of approximately $320 million to $325 million. At the mid-point of the range, our outlook represents approximately 20% growth over fiscal 2022 ICL sales of approximately $270 million. The actions we are taking, and the feedback from our customers and their happy EVO patients, make us confident that we will continue to build upon our position as the fastest growing company within the refractive industry in our target markets.”

Financial Overview – Q2 2023

During the quarter, the Company recorded various accounting adjustments related to its Other Products, specifically its non-core Cataract IOL business which the Company had previously announced it will no longer support after fiscal 2023. These adjustments included a $0.7 million reduction in net sales related to sales return reserve of certain IOL products; $2.8 million in inventory reserves related to IOL products; $0.2 million impairment of intangible assets; and a $0.4 million tax benefit; in each case related to Other Products. Please refer to the reconciliation of GAAP to Non-GAAP in the Financial Metrics Excluding Other Product Cataract IOL Adjustments table for the impact on various financial measures.

Net sales were $92.3 million for the second quarter of 2023, up 14% compared to $81.1 million reported in the prior year quarter. The sales increase in the second quarter was driven by ICL sales growth of 19% and ICL unit growth of 21%, both as compared to the prior year period. In addition to the markets noted above, ICL units in EMEA markets were down 23% (with European markets up 6%, Latin America markets up 19%, and Middle East markets down 67%), primarily due to an inability to ship ICLs into one country as a result of changes in product labeling requirements. Other Product sales for the second quarter of 2023 were ($0.8) million compared to $3.2 million in the prior year quarter, reflecting a $2.5 million reduction in Cataract IOL sales and a $1.5 million decrease in other product sales due to decreased sales of cataract injector parts and sales return reserves related to Cataract IOLs. Adjusted Net Sales which reflects an adjustment for the $0.7 million reduction related to sales return reserve for Other Products was $93.0 million for the second quarter.

Gross profit margin for the second quarter of 2023 was 76.6% compared to the prior year quarter of 78.8%. Factors impacting gross margin in the second quarter of 2023, as compared to the prior year quarter include inventory reserves related to the Other Products Cataract IOL business. Adjusted Gross Profit Margin which reflects an adjustment for the $2.8 million in inventory reserves related to Other Products was 79.8% for the second quarter.

Operating expenses for the second quarter of 2023 were $62.1 million compared to the prior year quarter of $46.9 million. General and administrative expenses were $18.1 million compared to the prior year quarter of $14.0 million. The increase in general and administrative expenses was due to increased compensation related expenses, outside services and facilities costs. Selling and marketing expenses were $32.3 million compared to the prior year quarter of $24.2 million. The increase in selling and marketing expenses is due to increased advertising and promotional activities, compensation related expenses, trade shows and sales meetings. Research and development expenses were $11.8 million compared to the prior year quarter of $8.6 million. The increase in research and development expenses is due to increased compensation related expenses and clinical trial expenses related to U.S. post-approval studies. Adjusted Operating expenses which reflects an adjustment for the $0.2 million impairment of intangible assets related to Other Products was $62.0 million.

Net income for the second quarter of 2023 was $6.1 million or $0.12 per diluted share compared with net income of $13.0 million or $0.26 per diluted share for the prior year quarter. The year over year decrease in net income is attributable to higher operating expenses partially offset by higher gross profit and interest income. Adjusted Net Income for the second quarter of 2023 was $19.7 million or $0.40 per diluted share compared to $20.7 million or $0.42 per diluted share for the prior year quarter. This includes $3.3 million reduction in net income or $(0.07) per diluted share resulting in Adjusted Net Income for ICL of $9.4 million or $0.19 per diluted share for the second quarter.

Cash, cash equivalents, and investments available for sale at June 30, 2023, totaled $209.5 million, compared to $225.5 million at end of the fourth quarter of 2022.

¹ Refractive Surgery Council, RSC Quarterly Statistical Program, Q2 2023 Report, U.S. refractive procedure volumes down 14.9% Y/Y in Q2 2023 and down 9.1% sequentially from Q1 2023.

Conference Call

The Company will host a conference call and webcast today, Wednesday, August 2 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Conference ID 99981426), please dial 888-259-6580 for domestic participants and 206-962-3782 for international participants. The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.

A taped replay of the conference call (Replay Code 981426) will be available beginning approximately one hour after the call’s conclusion for seven days. This replay can be accessed by dialing 877-674-7070 for domestic callers and 416-764-8692 for international callers. An archived webcast will also be available at www.staar.com.

Use of Non-GAAP Financial Measures

This press release includes supplemental Non-GAAP financial information, which STAAR believes investors will find helpful in understanding its operating performance. Non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.

“Adjusted Net Income” and “Adjusted Net Income for ICL” exclude the following items that are included in “Net Income” as calculated in accordance with U.S. generally accepted accounting principles (“GAAP”): Cataract IOL sales return reserve, Cataract IOL inventory reserve, Cataract IOL intangible impairment, income tax benefit on Cataract IOL Adjusted Net Income also excludes gain or loss on foreign currency transactions, stock-based compensation expenses, and valuation allowance adjustments (if any). Management believes that “Adjusted Net Income” and “Adjusted Net Income for ICL” are useful to investors in gauging the outcome of the key drivers of the business performance: the ability to increase sales revenue and our ability to increase profit margin by improving the mix of high value products while reducing the costs over which management has control.

Management has excluded accounting adjustments related to exiting the Company’s non-core Cataract IOL business. These accounting adjustments include sales returns reserve, excess inventory reserves, an impairment charge related to cataract IOLs and the associated tax benefit of these adjustments. The Company has excluded these items in order to focus on its core ICL business as the Company will continue tapering the manufacturing of cataract IOLs, though it will continue to support these products through the end of 2023, as supplies permit. Management believes that disclosing Adjusted Net Income and Adjusted Net Income for ICL excluding these accounting adjustments is useful to investors in gauging the performance of its core ICL business.

For the reasons referenced above in connection with calculating Adjusted Net Income and Adjusted Net Income for ICL, management also supplements the Company’s GAAP consolidated financial statements and GAAP financial measures with other Non-GAAP financial measures, comprising of Adjusted Net Sales, Adjusted Cost of Sales, Adjusted Gross Profit Margin, Adjusted Operating Expenses, Adjusted Income Tax Provision, which in each case exclude the impact of any accounting adjustments related to the exiting of the Company’s non-core Cataract IOL business. The Company believes that these Non-GAAP financial measures provide additional insight into the ongoing financial results of its business which investors find useful to gauge the performance of its core ICL business.

Management has also excluded from the calculation of Adjusted Net Income gains and losses on foreign currency transactions because of the significant fluctuations that can result from period to period as a result of market driven factors. Stock-based compensation expenses consist of expenses for stock options and restricted stock under the Financial Accounting Standards Board’s Accounting Standards Codification (ASC) 718. Valuation allowance adjustments can occur from time to time based on forecasted changes in operating results until all net operating loss carryforwards are fully utilized. In calculating Adjusted Net Income, STAAR excludes stock-based compensation expenses and valuation allowance adjustments (if any) because they are non-cash expenses and because of the considerable judgment involved in calculating their values. In addition, these expenses tend to be driven by fluctuations in the price of our stock and not by the same factors that generally affect our other business expenses.

The Company also uses Constant Currency as a Non-GAAP financial measure to exclude the effects of currency fluctuations on net sales. The Company conducts a significant part of its activities outside the U.S. It receives sales revenue and pays expenses principally in U.S. dollars, Swiss francs, Japanese yen and euros. The exchange rates between dollars and non-U.S. currencies can fluctuate greatly and can have a significant effect on the Company’s results when reported in U.S. dollars. In order to compare the Company's performance from period to period without the effect of currency, the Company will apply the same average exchange rate applicable in the prior period, or the "constant currency" rate to sales or expenses in the current period as well. Because changes in currency are outside of the control of the Company and its managers, management finds this Non-GAAP measure useful in determining the long-term progress of its initiatives and determining whether its managers are achieving their performance goals. The Company believes that the Non-GAAP constant-currency sales results measures provided in this press release are similarly useful to investors to give insight on long term trends in the Company's performance without the external effect of changes in relative currency values. The table provided in this press release shows sales results calculated in accordance with GAAP, the effect of currency, and the resulting Non-GAAP measure expressed in constant currency.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™ product line. More than 2,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com.

Safe Harbor

All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2023 or prospects for achieving such plans, expectations for sales, revenue, margin, expenses or earnings, and any statements of assumptions underlying any of the foregoing, including those relating to financial performance in the quarter and fiscal year 2023. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include risks and uncertainties related to the COVID-19 pandemic and related public health measures, as well as the factors set forth in the Company’s Annual Report on Form 10-K for the year ended December 30, 2022 under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investor Information” section of the company’s website under the heading “SEC Filings.” We disclaim any intention or obligation to update or revise any financial projections or forward-looking statement due to new information or events. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: global economic conditions; the impact of the COVID-19 pandemic on markets; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before approval, or to take enforcement action; international trade disputes; and the willingness of surgeons and patients to adopt a new or improved product and procedure.

We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the ‘Investor Relations’ sections. Accordingly, investors should monitor such portions of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts.

Consolidated Balance Sheets
(in 000's)
Unaudited
		June 30, 2023				December 30, 2022
ASSETS
Current assets:
Cash and cash equivalents		$	94,695			$	86,480
Investments available for sale			97,312				125,159
Accounts receivable trade, net			94,442				62,447
Inventories, net			25,482				24,161
Prepayments, deposits, and other current assets			16,072				13,476
Total current assets			328,003				311,723
Investments available for sale			17,525				13,902
Property, plant, and equipment, net			55,924				50,921
Finance lease right-of-use assets, net			257				342
Operating lease right-of-use assets, net			31,530				30,270
Intangible assets, net			-				173
Goodwill			1,786				1,786
Deferred income taxes			4,672				4,824
Other assets			954				957
Total assets		$	440,651			$	414,898
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable		$	11,441			$	11,576
Obligations under finance leases			162				169
Obligations under operating leases			4,013				3,524
Allowance for sales returns			6,653				5,706
Other current liabilities			31,925				30,741
Total current liabilities			54,194				51,716
Obligations under finance leases			125				210
Obligations under operating leases			28,189				27,136
Deferred income taxes			1,295				1,489
Asset retirement obligations			101				220
Pension liability			3,050				1,935
Total liabilities			86,954				82,706
Stockholders' equity:
Common stock			485				482
Additional paid-in capital			419,594				404,189
Accumulated other comprehensive income (loss)			(2,521	)			156
Accumulated deficit			(63,861	)			(72,635	)
Total stockholders' equity			353,697				332,192
Total liabilities and stockholders' equity		$	440,651			$	414,898

Consolidated Statements of Income
(In 000's except for per share data)
Unaudited
		Three Months Ended																			Six Months Ended
		% of		June 30, 2023				% of		July 1, 2022				Fav (Unfav)							% of		June 30, 2023				% of		July 1, 2022				Fav (Unfav)
		Sales						Sales						Amount				%			Sales						Sales						Amount				%
Net sales		100.0	%	$	92,306			100.0	%	$	81,101			$	11,205			13.8	%		100.0	%	$	165,834			100.0	%	$	144,301			$	21,533			14.9	%
Cost of sales		23.4	%		21,580			21.2	%		17,229				(4,351	)		-25.3	%		22.6	%		37,546			21.6	%		31,165				(6,381	)		-20.5	%
Gross profit		76.6	%		70,726			78.8	%		63,872				6,854			10.7	%		77.4	%		128,288			78.4	%		113,136				15,152			13.4	%
Selling, general and administrative expenses:
General and administrative		19.6	%		18,097			17.2	%		13,983				(4,114	)		-29.4	%		21.8	%		36,195			18.0	%		25,923				(10,272	)		-39.6	%
Selling and marketing		35.0	%		32,277			29.9	%		24,233				(8,044	)		-33.2	%		35.4	%		58,631			28.8	%		41,503				(17,128	)		-41.3	%
Research and development		12.7	%		11,755			10.7	%		8,636				(3,119	)		-36.1	%		13.3	%		22,065			11.4	%		16,577				(5,488	)		-33.1	%
Total selling, general, and administrative expenses		67.3	%		62,129			57.8	%		46,852				(15,277	)		-32.6	%		70.5	%		116,891			58.2	%		84,003				(32,888	)		-39.2	%
Operating income		9.3	%		8,597			21.0	%		17,020				(8,423	)		-49.5	%		6.9	%		11,397			20.2	%		29,133				(17,736	)		-60.9	%
Other income (expense), net:
Interest income, net		1.9	%		1,775			0.1	%		43				1,732			4027.9	%		2.2	%		3,597			0.0	%		37				3,560			9621.6	%
Loss on foreign currency transactions		-2.0	%		(1,890	)		-2.3	%		(1,860	)			(30	)		-1.6	%		-1.1	%		(1,856	)		-1.9	%		(2,775	)			919			33.1	%
Royalty income		0.0	%		0			0.2	%		177				(177	)		-100.0	%		0.0	%		0			0.3	%		450				(450	)		-100.0	%
Other income, net		0.0	%		10			0.1	%		89				(79	)		-88.8	%		0.0	%		73			0.1	%		151				(78	)		-51.7	%
Total other income (expense), net		-0.1	%		(105	)		-1.9	%		(1,551	)			1,446			93.2	%		1.1	%		1,814			-1.5	%		(2,137	)			3,951			184.9	%
Income before provision for income taxes		9.2	%		8,492			19.1	%		15,469				(6,977	)		-45.1	%		8.0	%		13,211			18.7	%		26,996				(13,785	)		-51.1	%
Provision for income taxes		2.6	%		2,428			3.0	%		2,431				3			0.1	%		2.7	%		4,437			3.0	%		4,356				(81	)		-1.9	%
Net income		6.6	%	$	6,064			16.1	%	$	13,038			$	(6,974	)		-53.5	%		5.3	%	$	8,774			15.7	%	$	22,640			$	(13,866	)		-61.2	%
Net income per share - basic				$	0.13					$	0.27												$	0.18					$	0.47
Net income per share - diluted				$	0.12					$	0.26												$	0.18					$	0.46
Weighted average shares outstanding - basic					48,418						47,889													48,333						47,822
Weighted average shares outstanding - diluted					49,516						49,223													49,524						49,264

Consolidated Statements of Cash Flows
(in 000's)
Unaudited
		Three Months Ended								Six Months Ended
		June 30, 2023				July 1, 2022				June 30, 2023				July 1, 2022
Cash flows from operating activities:
Net income		$	6,064			$	13,038			$	8,774			$	22,640
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation of property and equipment			1,285				1,030				2,398				2,024
Amortization of long-lived intangibles			164				7				171				15
Accretion/Amortization of investments available for sale			(841	)			-				(1,824	)			-
Deferred income taxes			18				-				75				-
Change in net pension liability			(614	)			11				(627	)			52
Stock-based compensation expense			8,423				5,754				14,488				9,648
Change in asset retirement obligation			(107	)			-				(107	)			-
Loss on disposal of property and equipment			24				-				24				-
Provision for sales returns and bad debts			1,381				994				1,004				800
Inventory provision			3,016				994				3,630				1,428
Changes in working capital:
Accounts receivable			(31,234	)			(16,210	)			(32,344	)			(20,137	)
Inventories			(462	)			(342	)			(4,382	)			(1,825	)
Prepayments, deposits and other current assets			1,584				2,245				(2,665	)			(2,260	)
Accounts payable			1,721				575				(1,447	)			3,243
Other current liabilities			3,272				5,150				1,432				(6,992	)
Net cash provided by (used in) operating activities			(6,306	)			13,246				(11,400	)			8,636
Cash flows from investing activities:
Acquisition of property and equipment			(3,014	)			(5,271	)			(5,915	)			(7,810	)
Purchase of investments available for sale			(15,157	)			-				(42,602	)			-
Proceeds from sale or maturity of investments available for sale			28,343				-				68,622				-
Net cash provided by (used in) investing activities			10,172				(5,271	)			20,105				(7,810	)
Cash flows from financing activities:
Repayment of finance lease obligations			(40	)			(27	)			(82	)			(45	)
Repurchase of employee common stock for taxes withheld			(135	)			-				(1,984	)			-
Proceeds from vested restricted stock and exercise of stock options			1,477				2,234				2,007				3,146
Net cash provided by (used in) financing activities			1,302				2,207				(59	)			3,101
Effect of exchange rate changes on cash and cash equivalents			(441	)			(759	)			(431	)			(1,143	)
Increase in cash and cash equivalents			4,727				9,423				8,215				2,784
Cash and cash equivalents, at beginning of the period			89,968				193,067				86,480				199,706
Cash and cash equivalents, at end of the period		$	94,695			$	202,490			$	94,695			$	202,490

Reconciliation of Non-GAAP Financial Measure
Financial Metrics Excluding Other Product Cataract IOL Adjustments
(in 000's)
Unaudited
		Three Months Ended																		Six Months Ended
		% of Sales		June 30, 2023				% of Sales		July 1, 2022			Fav (Unfav)							% of Sales		June 30, 2023				% of Sales		July 1, 2022			Fav (Unfav)
													Amount				%														Amount				%
Net sales:
Net sales, GAAP		100.0	%	$	92,306			100.0	%	$	81,101		$	11,205			13.8	%		100.0	%	$	165,834			100.0	%	$	144,301		$	21,533			14.9	%
Add: Cataract IOL sales return reserve					742						-			742									742						-			742
Adjusted Net sales, Non-GAAP		100.0	%	$	93,048			100.0	%	$	81,101		$	11,947			14.7	%		100.0	%	$	166,576			100.0	%	$	144,301		$	22,275			15.4	%
Cost of sales:
Cost of sales, GAAP		23.4	%	$	21,580			21.2	%	$	17,229		$	(4,351	)		-25.3	%		22.6	%	$	37,546			21.6	%	$	31,165		$	(6,381	)		-20.5	%
Less: Cataract IOL inventory reserve					(2,800	)					-			2,800									(2,800	)					-			2,800
Adjusted Cost of sales, Non-GAAP		20.2	%	$	18,780			21.2	%	$	17,229		$	(1,551	)		-9.0	%		20.9	%	$	34,746			21.6	%	$	31,165		$	(3,581	)		-11.5	%
Gross profit and gross profit margin:
Gross profit and gross profit margin, GAAP		76.6	%	$	70,726			78.8	%	$	63,872		$	6,854			10.7	%		77.4	%	$	128,288			78.4	%	$	113,136		$	15,152			13.4	%
Add: Cataract IOL sales return reserve					742						-			742									742						-			742
Add: Cataract IOL inventory reserve					2,800						-			2,800									2,800						-			2,800
Adjusted Gross profit and gross profit margin, Non-GAAP		79.8	%	$	74,268			78.8	%	$	63,872		$	10,396			16.3	%		79.1	%	$	131,830			78.4	%	$	113,136		$	18,694			16.5	%
Operating expenses:
Operating expenses, GAAP		67.3	%	$	62,129			57.8	%	$	46,852		$	(15,277	)		-32.6	%		70.5	%	$	116,891			58.2	%	$	84,003		$	(32,888	)		-39.2	%
Less: Cataract IOL intangible impairment					(154	)					-			154									(154	)					-			154
Adjusted Operating expenses, Non-GAAP		66.6	%	$	61,975			57.8	%	$	46,852		$	(15,123	)		-32.3	%		70.1	%	$	116,737			58.2	%	$	84,003		$	(32,734	)		-39.0	%
Provision for income taxes:
Provision for income taxes, GAAP		2.6	%	$	2,428			3.0	%	$	2,431		$	3			0.1	%		2.7	%	$	4,437			3.0	%	$	4,356		$	(81	)		-1.9	%
Add: Income tax benefit on Cataract IOL					405						-			(405	)								405						-			(405	)
Adjusted Provision for income taxes, Non-GAAP		3.0	%	$	2,833			3.0	%	$	2,431		$	(402	)		-16.5	%		2.9	%	$	4,842			3.0	%	$	4,356		$	(486	)		-11.2	%

Reconciliation of Non-GAAP Financial Measure
Adjusted Net Income and Net Income Per Share
(in 000's)
Unaudited		Three Months Ended						Six Months Ended
		June 30, 2023			July 1, 2022			June 30, 2023			July 1, 2022
Net income (as reported)		$	6,064		$	13,038		$	8,774		$	22,640
Less
Cataract IOL sales return reserve			742			-			742			-
Cataract IOL inventory reserve			2,800			-			2,800			-
Cataract IOL intangible impairment			154			-			154			-
Income tax benefit on Cataract IOL			(405	)		-			(405	)		-
Adjusted net income for ICL			9,355			13,038			12,065			22,640
Less:
Foreign currency impact			1,890			1,860			1,856			2,775
Stock-based compensation expense			8,423			5,754			14,488			9,648
Net income (adjusted)		$	19,668		$	20,652		$	28,409		$	35,063
Net income per share, basic (as reported)		$	0.13		$	0.27		$	0.18		$	0.47
Cataract IOL sales return reserve			0.02			-			0.02			-
Cataract IOL inventory reserve			0.06			-			0.06			-
Cataract IOL intangible impairment			-			-			-			-
Income tax benefit on Cataract IOL			(0.01	)		-			(0.01	)		-
Adjusted net income for ICL per share, basic			0.19			0.27			0.25			0.47
Foreign currency impact			0.04			0.04			0.04			0.06
Stock-based compensation expense			0.17			0.12			0.30			0.20
Net income per share, basic (adjusted)		$	0.41		$	0.43		$	0.59		$	0.73
Net income per share, diluted (as reported)		$	0.12		$	0.26		$	0.18		$	0.46
Cataract IOL sales return reserve			0.01			-			0.01			-
Cataract IOL inventory reserve			0.06			-			0.06			-
Cataract IOL intangible impairment			-			-			-			-
Income tax benefit on Cataract IOL			(0.01	)		-			(0.01	)		-
Adjusted net income for ICL per share, diluted			0.19			0.26			0.24			0.46
Foreign currency impact			0.04			0.04			0.04			0.06
Stock-based compensation expense			0.17			0.12			0.29			0.19
Net income per share, diluted (adjusted)		$	0.40		$	0.42		$	0.57		$	0.71
Weighted average shares outstanding - Basic			48,418			47,889			48,333			47,822
Weighted average shares outstanding - Diluted			49,516			49,223			49,524			49,264
Note: Net income per share (adjusted), basic and diluted, may not add due to rounding

STAAR Surgical Company
Reconciliation of Non-GAAP Financial Measure
Constant Currency Sales
(in 000's)
Unaudited
	Three Months Ended
	June 30, 2023			Effect of			Constant				July 1, 2022			As Reported						Constant Currency
Sales				Currency			Currency							$ Change			% Change			$ Change			% Change
ICL	$	93,112		$	390		$	93,502			$	77,922		$	15,190		19.5	%		$	15,580		20.0	%
Cataract IOL		40			2			42				2,547			(2,507	)	-98.4	%			(2,505	)	-98.4	%
Other		(846	)		(15	)		(861	)			632			(1,478	)	-233.9	%			(1,493	)	-236.2	%
Other Products		(806	)		(13	)		(819	)			3,179			(3,985	)	-125.4	%			(3,998	)	-125.8	%
Total Sales	$	92,306		$	377		$	92,683			$	81,101		$	11,205		13.8	%		$	11,582		14.3	%
	Six Months Ended
	June 30, 2023			Effect of			Constant				July 1, 2022			As Reported						Constant Currency
Sales				Currency			Currency							$ Change			% Change			$ Change			% Change
ICL	$	163,737		$	2,116		$	165,853			$	136,597		$	27,140		19.9	%		$	29,256		21.4	%
Cataract IOL		1,516			159			1,675				5,449			(3,933	)	-72.2	%			(3,774	)	-69.3	%
Other		581			112			693				2,255			(1,674	)	-74.2	%			(1,562	)	-69.3	%
Other Products		2,097			271			2,368				7,704			(5,607	)	-72.8	%			(5,336	)	-69.3	%
Total Sales	$	165,834		$	2,387		$	168,221			$	144,301		$	21,533		14.9	%		$	23,920		16.6	%

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20230802056490/en/

Investors and Media

Brian Moore

Vice President, Investor, Media Relations and Corporate Development

(626) 303-7902, Ext. 3023

bmoore@staar.com

Source: STAAR Surgical Company

FAQ

What were STAAR Surgical's net sales for Q2 2023?

STAAR Surgical reported net sales of $92.3 million for Q2 2023.

How much were the ICL sales for Q2 2023?

ICL sales reached a record high of $93.1 million for Q2 2023.

What was the gross margin for Q2 2023?

The gross margin for Q2 2023 was 76.6%.

What was the net income per share for Q2 2023?

The net income per share for Q2 2023 was $0.12.

How much cash, cash equivalents, and investments did STAAR Surgical have at the end of Q2 2023?

STAAR Surgical had $209.5 million in cash, cash equivalents, and investments at the end of Q2 2023.